| |
Headline |
Date
|
| |
Etravirine (TMC125, Intelence) granted accelerated approval in US
|
21.01.08 |
| |
Triple-class failure emerges slowly in UK patients
|
07.12.07 |
| |
Start treatment when CD4 cell count is 350, say revised US guidelines
|
05.12.07 |
| |
Bevirimat 300mg oral solution dose does well in study
|
26.10.07 |
| |
Undetectable viral load is goal for all, together with earlier treatment, say new European treatment guidelines
|
25.10.07 |
| |
Raltegravir receives accelerated approval from the FDA
|
15.10.07 |
| |
Roche abandon Biojector 2000 for T-20 administration
|
04.10.07 |
| |
Most patients on incompletely suppressive therapy maintain CD4 counts and stable viral loads
|
04.10.07 |
| |
ICAAC: 48-week results show maraviroc still potent in highly treatment-experienced
|
20.09.07 |
| |
ICAAC: Raltegravir shows sustained effect in highly treatment-experienced patients
|
19.09.07 |
| |
ICAAC: Vicriviroc safe, effective after 2 years, phase III studies start soon
|
19.09.07 |
| |
ICAAC: Best response to elvitegravir seen when used with T-20 and other active agents
|
19.09.07 |
| |
T-20 increases tipranavir levels but does not increase risk of liver side-effects
|
12.09.07 |
| |
IAS: Maraviroc produces best results when combined with another active drug
|
14.08.07 |
| |
TMC-125 and darunavir show strong effect in highly treatment-experienced, even without T-20
|
06.07.07 |
| |
Merck hopes for US integrase inhibitor license by October
|
28.06.07 |
| |
Is there any clinical benefit to staying on a failing regimen?
|
13.04.07 |
| |
Darunavir looking promising as companion for agents in new HIV drug classes
|
05.04.07 |
| |
Next generation NRTI, apricitabine (ATC), shows early promise
|
19.03.07 |
| |
CROI: Experimental 'salvage' integrase inhibitor, elvitegravir (GS-9137) appears potent at higher doses
|
06.03.07 |
